Gemcitabine

for the treatment of cancer

Technology Guidance from the MOH Drug Advisory Committee

Guidance Recommendations

Following an evaluation of gemcitabine for advanced bladder cancer and non-small-cell lung cancer, the MOH Drug Advisory Committee has recommended to list gemcitabine 1g, 2g and 200mg on the MOH Standard Drug List 2 (SDL2) in view of its comparable clinical efficacy and safety to other standard chemotherapy regimens and low annual cost of subsidy.

This recommendation means that subsidies will apply to gemcitabine for the indications registered in Singapore:

- First-line treatment of locally advanced or metastatic non-small cell lung cancer in combination with cisplatin and palliative treatment of adult patients with locally advanced or metastatic non-small cell lung cancer;
- Treatment of adult patients with locally advanced or metastatic adenocarcinoma of the pancreas;
- Treatment of advanced bladder cancer in combination with cisplatin;
- Treatment of unresectable, locally recurrent or metastatic breast cancer who have relapsed following adjuvant or neoadjuvant chemotherapy in combination with paclitaxel.

Published on 3 May 2017

ACE
agency for
care effectiveness

About the Agency

The Agency for care effectiveness (ACE) is the national health technology assessment agency in Singapore residing within the Ministry of Health. It conducts evaluations to inform the subsidy of treatments, and produces guidance on the appropriate use of treatments for public hospitals and institutions in Singapore. When using the guidance, the responsibility for making decisions appropriate to the circumstances of the individual patient remains with the healthcare professional.

Find out more about ACE at www.ace-hta.gov.sg/about

Head (Evaluation)
Agency for Care Effectiveness
Email: ACE_HTA@moh.gov.sg